Search Clinical Trials in the European Union
Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1581-1600 of 2,120 trials
Healthy Volunteers6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine
Postmenopausal OsteoporosisEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinologyOrthopedics and TraumatologyRheumatology
Carotid Artery Atherosclerosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology
Polypoidal Choroidal Vasculopathy>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOphthalmology
Chronic Lymphocytic Leukemia (CLL)1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology
Stage II/III Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology
Chronic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology
Metastatic Non-small Cell Lung CancerConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncology
Ischemic Stroke1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology
Episodic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology
Inguinal Hernia1-2 yearsMonitoring phase (IV)Standard MedicinesInternal MedicineOrthopedics and Traumatology
Non-small cell lung cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology
Pulmonary Hypertension>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine
Prosthetic Joint Infection>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyOtolaryngology
Early Triple-Negative Breast Cancer (TNBC)6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology